Fosamax Osteonecrosis of the Jaw Causation: How Fosamax Triggers Osteonecrosis of the Jaw Pathophysiology

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Assessment

The legacy of general health and science communication has long emphasized the importance of understanding how everyday exposures—whether from lifestyle, environment, or medical interventions—can influence well-being. In the context of mass production, this heritage provides a foundation for examining how widely distributed products may intersect with population health. Historically, public health messaging has focused on broad risk factors, such as diet or exercise, to prevent chronic conditions. However, as manufacturing scales and therapeutic agents become more prevalent, the scope of inquiry must expand to include occupational and consumer exposure scenarios. This transition pivots from general health education toward a more targeted concern: the potential for specific pharmaceutical agents, when produced and prescribed at scale, to introduce unintended health risks in certain populations. The shift acknowledges that while mass production improves access to treatments, it also necessitates rigorous surveillance of adverse outcomes that may emerge only after widespread use. In particular, the pathway from routine clinical application to rare but serious complications requires careful examination. The focus here moves from abstract health principles to the concrete reality of how a widely manufactured drug, such as a bisphosphonate, might be linked to a specific tissue-level response in the jaw, without delving into mechanistic details. This sets the stage for exploring the occupational and clinical implications of such exposures.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the need for targeted risk assessment, we now examine Fosamax (alendronate sodium), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibiting bone resorption by osteoclasts, which reduces bone turnover. However, this suppression of normal bone remodeling has been linked to a serious adverse effect: osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including FOSAMAX (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Pathophysiology of Fosamax-Induced Osteonecrosis of the Jaw

The pathophysiology linking Fosamax to ONJ involves several mechanistic pathways. Bisphosphonates like alendronate accumulate in bone, particularly in areas of high turnover such as the jaw. The drug's potent inhibition of osteoclast activity disrupts the normal balance between bone resorption and formation. This leads to a reduction in the ability of the jawbone to repair microdamage and remodel in response to mechanical stress or infection. The multiscale characterization of jawbone treated with osteoporosis therapeutic agents provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Studies in animal models have shown that bisphosphonate treatment alters the mechanical stability of teeth in the alveolar socket and changes tissue mineral density distribution and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These changes may predispose the jawbone to necrosis, especially when additional stressors such as dental procedures or local infection are present.

Risk Factors and Clinical Considerations

Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This wide range complicates the establishment of a clear timeline between exposure and documented harm. Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of FOSAMAX, the percentages of patients with these symptoms were similar in the FOSAMAX and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse effect, its incidence in clinical trials was low and not statistically different from placebo, which may have implications for the adequacy of warnings.

Causation and Implications for Affected Patients

Regarding causation-related considerations for affected patients, the evidence indicates that Fosamax can be a contributing factor in the development of ONJ, particularly when other risk factors are present. The pathophysiology involves the drug's suppression of bone turnover in the jaw, leading to impaired healing and increased susceptibility to necrosis. The label advises discontinuation of the drug if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the optimal duration of use has not been determined, and for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that long-term exposure may increase risk, but the label does not provide specific guidance on monitoring for ONJ. In summary, Fosamax triggers osteonecrosis of the jaw through a pathophysiological mechanism involving suppression of bone remodeling in the jawbone, which is exacerbated by dental procedures, infection, and other risk factors. The timeline from exposure to harm is variable, and while warnings exist, the low incidence in clinical trials and the multifactorial nature of ONJ may affect the perception of risk. Patients and healthcare providers should be aware of these risks and consider preventive dental care and monitoring.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which Fosamax causes osteonecrosis of the jaw?

Fosamax (alendronate) inhibits osteoclast activity, suppressing bone remodeling. This leads to accumulation of microdamage and impaired healing in the jawbone, especially after dental procedures or infection, predisposing to osteonecrosis (https://pubmed.ncbi.nlm.nih.gov/40345077).

What are the risk factors for developing osteonecrosis of the jaw while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures. Duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.